Meta-analysisindependent cross-checkabstract checked I-ODD-110 standard review
No sign in trials that SGLT2 drugs damage the brain
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.
Overview
Seminer A et al.. JAMA Neurol 2025 · PMID 40193122 · DOI 10.1001/jamaneurol.2025.0360
Dementia OR 1.20 (0.67-2.17) for SGLT2i, not significant; GLP-1 RA OR 0.55.
Does the study support the specific claim? No · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Assess dementia risk with cardioprotective diabetes drugs in RCTs.
- How was the study done?
Meta-analysis of 26 RCTs.
- How many people, animals or samples were studied?
164,531 participants.
- What was actually found?
No effect overall; benefit with GLP-1 RAs; SGLT2i neutral but imprecise.
- How large was the observed effect?
SGLT2i OR 1.20 (0.67-2.17).
- What do the results mean in everyday life?
Trials do not show brain damage from Forxiga-type drugs.
- What are the study's limitations?
Dementia rarely measured systematically.
- What does it say about Elawady's specific claim?
Does not support 'kills the brain'.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
A small effect in either direction.
Scientific in-depth review
1. Full reference
- Authors
- Seminer A et al.
- Journal
- JAMA Neurol
- Year
- 2025
- Identifier
- PMID 40193122 DOI 10.1001/jamaneurol.2025.0360
- Verification
- verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Not stated in abstract.
2. Research question
Do cardioprotective glucose-lowering drugs (SGLT2i, GLP-1 RA, metformin, pioglitazone) reduce dementia or cognitive impairment?
3. Study design and population
- Study design
- Meta-analysis – Systematic review and random-effects meta-analysis of RCTs
- Population
Participants in RCTs of these drug classes (mean age 64.4)
- Country
International
- Period
Searches to 11 July 2024
- Sample size
26 RCTs (164,531 participants); 23 reporting dementia (160,191)
- Inclusion and exclusion criteria
RCTs vs controls reporting dementia or cognitive scores
4. Methods and endpoints
- Exposure / intervention
SGLT2i (12 trials), GLP-1 RA (10), pioglitazone (1)
- Comparator
Controls (mostly placebo)
- Endpoints
Dementia or cognitive impairment; dementia subtypes; cognitive scores
- Statistical methods
Random-effects OR
5. Actual results
- Results
Overall OR 0.83 (0.60-1.14). GLP-1 RA OR 0.55 (0.35-0.86); SGLT2i OR 1.20 (0.67-2.17); heterogeneity between classes p=0.04.
- Absolute risks
Not reported in abstract.
- Authors' conclusion
No overall reduction; GLP-1 RAs were associated with a significant reduction in all-cause dementia.
6. Strengths
- RCT-only evidence
- Large sample
7. Weaknesses
- Dementia not a primary trial outcome; under-ascertainment likely
- Wide CI for SGLT2i
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Outcome ascertainment as adverse events.
9. Assessment of the statistical interpretation
SGLT2i CI 0.67-2.17 is wide (stats/C-ODD-06.py): neither harm nor benefit can be excluded; there is no randomised signal of brain damage.
10. Relevance to the specific claim
Tests whether SGLT2 inhibitors damage the brain in randomised data: no significant signal; observational studies suggest lower dementia risk (not added).
11. Independent contrary findings
Observational meta-analyses report lower dementia risk with SGLT2i (e.g. HR 0.68), but are confounding-prone.
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
No evidence for 'kills the brain'; evidence for benefit is limited to GLP-1 RAs.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | low |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | mixed |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Dedicated cognitive trials of SGLT2i.